C3a Receptor Inhibition Protects Brain Endothelial Cells Against Oxygen-glucose Deprivation/Reperfusion

Saif Ahmad1*, Adam Kindelin1, Shah Alam Khan1,2, Maaz Ahmed1, Md Nasrul Hoda3, Kanchan Bhatia1,4 and Andrew F. Ducruet1*

1Department of Neurosurgery, 2Department of Neurology, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Dignity Health, Phoenix, Arizona 85013, USA, 3Oman Medical College, Muscat 130, Sultanate of Oman, 4School of Mathematical and Natural Sciences, Arizona State University, Phoenix, AZ 85004, USA

The complement cascade is a central component of innate immunity which plays a critical role in brain inflammation. Complement C3a receptor (C3aR) is a key mediator of post-ischemic cerebral injury, and pharmacological antagonism of the C3a receptor is neuroprotective in stroke. Cerebral ischemia injures brain endothelial cells, causing blood brain barrier (BBB) disruption which further exacerbates ischemic neuronal injury. In this study, we used an in vitro model of ischemia (oxygen glucose deprivation; OGD) to investigate the protective effect of a C3aR antagonist (C3aRA, SB290157) on brain endothelial cells (bEnd.3). Following 24 hours of reperfusion, OGD-induced cell death was assessed by TUNEL and Caspase-3 staining. Western blot and immunocytochemistry were utilized to demonstrate that OGD upregulates inflammatory, oxidative stress and antioxidant markers (ICAM-1, Cox-2, Nox-2 and MnSOD) in endothelial cells and that C3aRA treatment significantly attenuate these markers. We also found that C3aRA administration restored the expression level of the tight junction protein occludin in endothelial cells following OGD. Interestingly, OGD/reperfusion injury increased the phosphorylation of ERK1/2 and C3aR inhibition significantly reduced the activation of ERK suggesting that endothelial C3aR may act via ERK signaling. Furthermore, exogenous C3a administration stimulates these same inflammatory mechanisms both with and without OGD, and C3aRA suppresses these C3a-mediated responses, supporting an antagonist role for C3aRA. Based on these results, we conclude that C3aRA administration attenuates inflammation, oxidative stress, ERK activation, and protects brain endothelial cells following experimental brain ischemia.

Key words: bEnd.3 cells, Ischemia, OGD, Inflammation, Oxidative stress

Received December 12, 2018, Revised April 9, 2019, Accepted April 10, 2019

*To whom correspondence should be addressed.
TEL: 1-602-406-3220, FAX: 1-602-406-4172
Saif Ahmad, e-mail: saif.ahmad@barrowneuro.org
Andrew F. Ducruet, e-mail: andrew.ducruet@barrowbrainandspine.com

INTRODUCTION

Ischemic stroke is the third leading cause of death and the leading cause of disability worldwide and claims around 130,000 lives annually. Ischemic stroke causes loss of brain function due to a reduction in cerebral blood flow which suppresses oxygen and glucose levels in the brain. This in turn triggers neuronal cell death and blood brain barrier (BBB) dysfunction via activation of in-
Complement C3aR Antagonism in Brain Endothelial Cells

MATERIALS AND METHODS

Chemicals and reagents
C3aR inhibitor (SB290157) was purchased from (Calbiochem, Darmstadt, Germany). Immortalized bEnd.3 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Dulbecco’s Modified Eagle Medium (DMEM/High Glucose, GE, Utah, USA), Pen strep (Gibco, USA), FBS (VWR, USA) and all reagents used were AR and molecular grade. TUNEL assay kit was obtained from AAT Bioquest (USA). Antibodies (monoclonal anti-mouse Caspase3; monoclonal anti-mouse C3aR; monoclonal anti-mouse ICAM-1; monoclonal anti-mouse occludin; monoclonal anti-mouse Cox-2; monoclonal gp91-phox and MnSOD) were obtained from Santa Cruz Biotechnology, CA, USA. Recombinant C3a (rmC3a) was obtained from R&D system (USA). Lectin was purchased from Vector Lab (USA). Protease inhibitor cocktail was purchased from Sigma (MO). RIPA extraction buffer was procured from Fisher Scientific (USA). All secondary fluorescent antibodies were purchased from Invitrogen (USA).

Cell culture, treatment and Oxygen-Glucose deprivation (OGD)
Endothelial cell culture was performed as previously described [32]. In brief, the immortalized mouse brain endothelial cell line (bEnd.3) was cultured in DMEM with high glucose (4.5 mg/ml) supplemented with 10% FBS, and antibiotic. The cells were incubated in a CO₂ incubator with 5% CO₂ at 37°C. OGD is used as an in vitro model which best mimics in vivo ischemia/reperfusion injury. Endothelial cells were deprived of glucose and oxygen [we changed the culture medium to oxygen-, glucose free balanced salt solution (EBSS-24010-043, Gibco, USA)] by transferring into an anaerobic chamber (0% O₂) for 3 hrs. After OGD, cells were returned to a normoxic incubator under 5% CO₂/95% air for 24 hours in complete medium. Normoxic bEnd.3 cells served as controls. C3aRA (10 µM in 0.1% DMSO) was added 1 hour prior to OGD. In the control group, volume equivalent 0.1% DMSO was added as vehicle. C3a (100N in PBS) was administered with and without C3aRA prior to OGD.

TUNEL assay
Apoptotic cell death was analyzed using a terminal deoxynucleotidyl transferase-mediated uridine 5’-triphosphate-biotin nick end labeling (TUNEL) assay kit (In Situ Cell Death Detection Fluorescent, Roche, Germany). In brief, bEnd.3 cells were grown on glass coverslips and after C3aRA treatment in the setting of OGD/reperfusion, cells were fixed with 4% PFA and then washed with 1X PBS three times. The fixed cells were permeabilized with 0.1% triton X-100 (PBS-T) for 5 minutes before incubating with fluorescein dUTP TUNEL reaction mixture for 1 h at 37°C. After the PBS wash, cells were counterstained with DAPI (Vector Laboratories, USA). The slides were evaluated under the fluorescence
microscope (Leica, Germany) and TUNEL positive nuclei were counted by researcher blinded to treatment. The experiment was repeated 3 times in the same environment and images were taken from 4 non-overlapping fields of coverslips. The percentage of TUNEL positive cells relative to the total number of cell nuclei counterstained with DAPI was used to calculate the TUNEL positive ratio (number of green nuclei/number of blue nuclei) × 100%.

**Immunocytochemistry**

bEnd.3 cells were plated on coverslips in 6 well plates (Corning, USA) and then subjected to OGD as described above. Cells were fixed using 4% PFA for 20 minutes at room temperature. For immunofluorescence study, samples were blocked with 10% goat serum in TBS with 0.5% Triton X-100 for 1 hr. after the washing with PBS-T (0.1% Triton X-100), primary antibodies (Caspase-3, C3aR, ICAM-1 and Cox-2; Santa Cruz Biotechnology, 1:50 dilution) were added and incubated overnight at 4°C. Cells were washed 3 times with PBS-T and then again incubated in fluorescein anti-mouse secondary antibodies (Invitrogen, 1:200), mounted with DAPI (Vector), and analyzed using fluorescence microscope (Keyence) by using 20 and 40 x objectives. Fluorescence intensity was measured by Image J software (NIH) [33].

**Western blot**

The bEnd.3 cells were homogenized in modified RIPA buffer (Upstate, Lake Placid, NY), containing 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% deoxycholate, supplemented with 40 mM NaF; 2 mM NaVO₄; 0.5 mM phenylmethylsulfonyl fluoride and 1:100 (v/v) of proteinase inhibitor cocktail (Sigma). Insoluble material was removed by centrifugation at 12,000 xg at 4°C for 30 min. Protein concentration was determined by DC Protein Assay (Bio-Rad, Hercules, CA). Equal amount of protein was loaded on SDS-PAGE (gradient gel - 4 to 20%; Pierce, Rockford, IL) and subsequently transferred to PVDF membrane.

![Fig. 1. C3aRA administration attenuates C3aR expression level after OGD. A-D) C3aR expression was observed by immunohistochemistry and Western blot. Data shown are the mean±SEM (n=5). **p<0.01, ***p<0.001, ****p<0.0001. Cont, control group; OGD, ischemic group; Cont+C3aRA, drug control; OGD+C3aRA, drug treatment.](https://doi.org/10.5607/en.2019.28.2.216)
(Biorad) and probed with specific antibodies (anti-mouse C3aR, Occludin, gp91-phox and MnSOD; 1:1000) overnight followed by 3 washes with TBS-T. Membranes were then incubated with secondary antibodies HRP conjugated for 1 h at RT and, after 3 washes with TBS, bands were visualized using the enhanced Amersham ECL western blotting detection kit (GE Healthcare, USA). Protein expression was detected as previously described [34]. The same membranes were re-probed using β-actin as an internal control. Quantification of immunoreactivity was performed using densitometry analysis in the standard fashion (Image J software/NIH) [33].

Statistical analysis

Quantitative data are presented as mean±SEM. Differences among experimental groups were analyzed by analysis of variance (one-way ANOVA) followed by Newman-Keuls multiple comparison tests. Significance was defined as p<0.05. Data were analyzed using Graph Pad PRISM software.

RESULTS

OGD promotes endothelial C3aR expression

In the present study, OGD led to a significant increase in C3aR protein expression level (22.2%, vs. 10.6% control) in bEnd.3 cells relative to control. Interestingly, C3aR antagonist administration (C3aRA; SB290157) significantly reduced (14.2%) the expression of C3aR protein compared following OGD (Fig. 1A–D).

C3aR antagonism attenuates endothelial apoptotic cell death following OGD

OGD promotes apoptotic cell death in bEnd3 cells [2]. To determine whether C3aR inhibition attenuates cell death, we inves-
tigated the effect of OGD on endothelial apoptosis using TUNEL assay and Caspase-3 staining (Fig. 2A–D). Both TUNEL and Caspase-3 staining showed increased apoptotic cell death (23.8% vs. 7.2% control) against OGD when compared with control group. C3aRA treatment significantly reduced the cell death (16.0%) subjected to OGD.

**C3aRA reduces endothelial Intracellular Adhesion Molecule-1 (ICAM-1) and Cox-2 expression following OGD**

ICAM-1 induces intracellular signaling in endothelial cells and its increased expression causes actin cytoskeleton reorganization, endothelial cell leakiness and junctional alterations [35]. OGD promotes ICAM-1 upregulation in bEnd.3 cells as compared with control. We found that C3aRA treatment significantly attenuates endothelial ICAM-1 expression. Double staining of ICAM-1 and C3aR demonstrates the co-localization of both the proteins in endothelial cells. Next, we observed a significant upregulation of endothelial Cox-2 expression following OGD which suppressed by C3aRA treatment. Upregulation of Cox-2, a rate limiting key enzyme in the synthesis of prostaglandins, mediates brain vascular inflammation [36]. These results suggest that C3aRA significantly attenuates expression of endothelial inflammatory markers following OGD which reflects decreased inflammation (Fig. 3A–C & Fig. 4A and 4B).

**C3aRA treatment reduces oxidative stress and increases antioxidant protein expression in endothelial cells following OGD**

NADPH oxidase subunit gp91phox (Nox2) contributes to endothelial dysfunction and permeability and is activated by hypoxia [37]. On the other hand, the antioxidant enzyme MnSOD plays a prominent protective role in vascular inflammation [38]. Here we demonstrated that OGD significantly elevated gp91-phox expression (19.9% vs. 11% control) and decreased MnSOD level (10.8% vs. 23.1% control) in bEnd.3 cells compared with controls. C3aRA treatment attenuated the expression of gp91-phox (15.8% vs. 100 μM).
OGD) and MnSOD (19.8% vs. OGD) following OGD respectively (Fig. 5A–D). These data suggest that C3aR antagonism reduces oxidative stress and may improve antioxidant activity following experimental OGD.

C3aRA restores endothelial expression of tight junction proteins and reduces the activation of pERK subjected to OGD

Tight junction proteins including ZO-1 and occludin play a key role in the maintenance of BBB integrity [39]. We observed decreased occludin expression (68% vs. Control) in endothelial cells subjected to OGD relative to controls. Administration of C3aRA restored occludin expression (54% vs. OGD) on following OGD (Fig. 6A and 6B). ERK1/2 activation has been reported to promote cell death in ischemia/reperfusion injury models [9]. Prior evidence has shown that C3aR activation leads to signaling mediated through pERK [40]. We therefore sought to evaluate levels of pERK in our model to demonstrate that endothelial C3aR inhibition functions through mediation of downstream pERK. We observed an increased expression of pERK1/2 (68% vs. control) in endothelial cells subjected to OGD relative to controls. Administration of C3aRA attenuated the expression of pERK1/2 (42% vs. OGD) following OGD (Fig. 6C and 6D).

C3a administration increased the activation of Caspase3, ICAM-1 and pERK following OGD

To determine the effect of exogenous C3a on bEnd3 cells following OGD, we found that C3a administration alone increased the expression of Caspase3, ICAM-1 and pERK. We also found that C3aRA in the presence of C3a significantly reduced the expres-
DISCUSSION

In the present study, we show that C3aR inhibition reduces endothelial cell death, attenuates inflammatory and oxidative stress signaling, and restores the expression of tight junction proteins following OGD. Cerebral microvascular endothelial cell (bEnd.3) culture represents an excellent model to study brain endothelial cell vascular dysfunction, and OGD/hypoxia activates inflammatory and oxidative stress mechanisms and degrades endothelial cell barrier function [10, 16, 41-43].

The complement system is a fundamental component of innate immunity and complement activation mediates ischemia/reperfusion injury across diverse organ systems [22, 44]. Endothelial expression of complement C3a receptor induces a variety of cellular responses, including activation of endothelial cells and increased endothelial permeability [22, 28]. Here, we investigated the protective role of C3aRA in an OGD induced endothelial cell culture model of experimental ischemia. In the present study, OGD pro-

Fig. 5. Effect of C3aR inhibition on gp91-phox and MnSOD expression level in endothelial cells following OGD. A) gp91-phox expression was determined by western blotting. B) gp91-phox densitometry analysis was done by Image J. C) Representative western blot showing endothelial expression of MnSOD. D) MnSOD densitometry analysis was done by Image J. The results represent the means±SEM of fold changes (n=4). *p<0.01, **p<0.001, ***p<0.0001. Cont, control group; OGD, ischemic group; Cont+C3aRA, drug control; OGD+C3aRA, drug treatment.

Fig. 6. C3aRA treatment attenuates tight junction protein occludin and pERK1/2 expression in endothelial cells against OGD. A) Endothelial expression of occludin was observed by Western blot. B) Occludin densitometry analysis was done by Image J. C) pERK and ERK expression assessed by Western blot. D) ERK densitometry analysis was done by Image J software (NIH). The results represent the means±SEM of fold changes (n=4). *p<0.01, **p<0.001, ***p<0.0001. Cont, control group; OGD, ischemic group; Cont+C3aRA, drug control; OGD+C3aRA, drug treatment.
Fig. 7. C3a administration alone increases the expression of Caspase3, ICAM-1 and pERK ½ in bEnd.3 cells but not C3aR following OGD. A–H) C3a treatment significantly enhanced the Caspase3, ICAM-1 and pERK level with OGD but not C3aR expression compared with OGD group. C3aRA treatment significantly reduced the level of these markers including C3aR with and without C3a. Color intensity was measured by Image J. The results represent the means±SEM of fold changes (n=5). *p<0.01, **p<0.001, ***p<0.0001. Cont, Control group; Cont+C3a, Cont+C3a+C3aRA; OGD, OGD, OGD+C3a, and OGD+C3a+C3aRA.
promoted endothelial cell expression of the C3aR. Administration of the C3aRA reduced C3aR expression levels. This is likely the result of an indirect feedback effect due to reduced inflammatory signaling and endothelial cell activation through abrogation of C3aR signaling, and further work is necessary to characterize this mechanism. We also found that treatment with C3aRA attenuated apoptotic cell death and C3aR expression level in bEnd.3 cells subjected to OGD followed by reperfusion. Further, OGD significantly increased the expression of the inflammatory markers ICAM-1 and Cox-2, and this expression was attenuated by C3aRA. Increased ICAM-1 expression has been shown to promote endothelial permeability, cytoskeletal reorganization and junctional alterations [35]. Cerebral endothelial ICAM-1 expression also promotes neutrophil infiltration through ischemic endothelium [22]. In the present study, C3aRA administration suppressed ICAM-1 expression, suggesting that C3aR plays an upstream role in ICAM-1 upregulation in ischemic endothelial cells. This has been observed previously in a murine model of middle cerebral artery occlusion, where the C3aRA-treated group exhibited significant reductions in ICAM-1 expression [22]. In the present study, we also demonstrated cyclooxygenase-2 (Cox-2) upregulation in endothelial cells following OGD. Cox-2, a key enzyme in the biosynthesis of prostaglandins, is upregulated in endothelial cells following administration of LPS and VEGF [45, 46]. Cox-2 serves a crucial role in the development of vascular inflammation [36]. Our findings suggest that complement C3aR may regulate post-ischemic endothelial Cox-2 expression and C3aR antagonism may be attenuating increased Cox-2 expression.

We further investigated the role of C3aRA on oxidative stress signaling pathways and observed that OGD increased NADPH oxidase subunit gp91-phox (Nox-2) expression. Several studies have suggested that ischemia/reperfusion generates increased reactive oxygen species (ROS) that in turn play a major role in endothelial cell (EC) activation and barrier function; and that the major source of ROS in endothelial cells is NADPH oxidase [47]. It is known that NADPH oxidase is activated by several factors including hypoxia, growth factors, cytokines and shear stress [48], and that Nox-2 is a critical component of endothelial NADPH oxidase [47]. Here, we found that C3aRA treatment significantly reduced Nox-2 expression in endothelial cells subjected to OGD, and our data is an agreement with a recent study showing that complement receptor 3 mediates NADPH oxidase activation [49]. On the other hand, we noted that mitochondrial superoxide dismutase (MnSOD) expression was suppressed in endothelial cells subjected to OGD and treatment with C3aRA restored its expression level significantly. There is a balance between intracellular ROS and antioxidant enzymes including SODs, whose main function is to convert O$_2^-$ to H$_2$O$_2$ [47]. MnSOD may participate in cellular defense in cerebral endothelial cells and there is profound MnSOD loss in cerebral endothelial cells due to oxidative stress [50]. Some reports suggest that MnSOD contributes to antioxidant defense in endothelial cells and the regulation of blood-brain barrier [51, 52]. Our data demonstrate that C3aRA treatment protects cerebral endothelial cells by supporting the intracellular antioxidant defense system against OGD induced oxidative stress.

The blood-brain barrier (BBB) serves to maintain the homeostasis of the central nervous system (CNS), and endothelial cells along with glia and pericytes comprise this important structure. Endothelial cells which constitute the BBB exhibit a specific phenotype characterized by the presence of tight junctions (TJs) and the expression of a uniquely polarized transport system [53]. Brain endothelial TJs are composed of integral membrane proteins, including occludin, which are crucial to BBB function [53, 54]. In the present study, we found that endothelial expression of occludin was suppressed following OGD and administration of C3aRA restored its expression. Similar results have been observed for expression of tight junction proteins in brain endothelial cells, which are downregulated by beta amyloid toxicity [43]. In another study, disruption of occludin expression in brain endothelial cells was reported following hypoxia/aglycemia [42]. Our results are in agreement with recent study in which hypoxia/OGD induces endothelial barrier dysfunction by downregulating tight junction proteins [41].

We further tested the hypothesis that C3aR activation functions through ERK1/2 pathway signaling in endothelial cells subjected to OGD. We found that the OGD significantly increased the phosphorylation of ERK1/2 and inhibition of C3aR attenuated the ERK1/2 expression level. It has been noted that ischemia induces activation of ERK1/2 signaling in cerebral endothelial cells which triggers endothelial cell death, and on the other hand ERK1 and ERK2 regulate endothelial cell proliferation and migration in angiogenesis [8, 9]. Interestingly, NADPH oxidase has been reported to be involved in activation of ERK signaling, and ERK1/2 cascade activates Cox-2 and ICAM-1 signaling in different disease models [49, 55, 56]. Moreover, SODs prevent ERK activation and cell death [9]. Our finding is an agreement with other studies which reported complement activation through C3a and C5a induces ERK1/2 signaling during ischemia/reperfusion injury [57, 58]. Together these data provide mechanistic insight into the fact that C3aR inhibition during ischemia/reperfusion may attenuate expression of Nox2/ICAM-1/Cox-2 and prevent endothelial cell death through ERK signaling. Next we administered exogenous C3a alone on bEnd3 cells with and without C3aRA following OGD. We found that C3a administration significantly increased endothelial cell expression...
Complement C3aR Antagonism in Brain Endothelial Cells

ACKNOWLEDGEMENTS

This work was supported by the Barrow Neurological Foundation (AFD) and BNF neurobiology trainee grant (SA). Authors gratefully acknowledge to Mr. Matthew Nelson, Mr. Jacob Busch and Ms. Natasha Dennis for administrative assistance. The authors thank the staff of Neuroscience Publications at Barrow Neurological Institute for assistance with figure preparation.

CONFLICT OF INTEREST

The authors report no conflict of interest with any person or Institute.

REFERENCES

1. Tornabene E, Brodin B (2016) Stroke and drug delivery--in vitro models of the ischemic blood-brain barrier. J Pharm Sci 105:398-405.
2. Zhang Y, Wang T, Yang K, Xu J, Ren L, Li W, Liu W (2016) Cerebral microvascular endothelial cell apoptosis after ischemia: role of enolase-phosphatase 1 activation and aci-reductone dioxygenase 1 translocation. Front Mol Neurosci 9:79.
3. He Y, Luan Z, Fu X, Xu X (2016) Overexpression of uncoupling protein 2 inhibits the high glucose-induced apoptosis of human umbilical vein endothelial cells. Int J Mol Med 37:631-638.
4. Tsai HY, Lin CP, Huang PH, Li SY, Chen JS, Lin FY, Chen JW, Lin SJ (2016) Coenzyme Q10 attenuates high glucose-induced endothelial progenitor cell dysfunction through AMP-activated protein kinase pathways. J Diabetes Res 2016:6384759.
5. Li W, Chen Z, Yan M, He P, Chen Z, Dai H (2016) The protective role of isorhamnetin on human brain microvascular endothelial cells from cytotoxicity induced by methylglyoxal and oxygen-glucose deprivation. J Neurochem 136:651-659.
6. Song J, Kang SM, Lee WT, Park KA, Lee KM, Lee JE (2014) Glutathione protects brain endothelial cells from hydrogen peroxide-induced oxidative stress by increasing nrf2 expression. Exp Neurobiol 23:93-103.
7. Yang J, Ahn HN, Chang M, Narasimhan P, Chan PH, Song YS (2013) Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice. J Neurochem 124:523-535.
8. Srinivasan R, Zabuawala T, Huang H, Zhang J, Gulati P, Fernandez S, Karlo JC, Landreth GE, Leone G, Ostrowski MC (2009) Erk1 and Erk2 regulate endothelial cell proliferation

Fig. 8. Schematic diagram showing OGD induced vascular dysfunction and the protective role of C3aRA. Solid arrow showing increase and broken arrow showing decrease. OGD, oxygen glucose deprivation.
and migration during mouse embryonic angiogenesis. PLoS One 4:e8283.

9. Narasimhan P, Liu J, Song YS, Massengale JL, Chan PH (2009) VEGF Stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. Stroke 40:1467-1473.

10. Liao LX, Zhao MB, Dong X, Jiang Y, Zeng KW, Tu PF (2016) TDB protects vascular endothelial cells against oxygen-glucose deprivation/reperfusion-induced injury by targeting miR-34a to increase Bcl-2 expression. Sci Rep 6:37959.

11. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, Fenart L (2007) Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 6:650-661.

12. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Fang S, Parsa AT (2010) Complement and the central nervous system: emerging roles in development, protection and regeneration. Immuno Cell Biol 88:781-786.

13. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058-1066.

14. Walport MJ (2001) Complement. Second of two parts. N Engl J Med 344:1140-1144.

15. Ducruet AF, Zacharia BE, Sosunov SA, Gigante PR, Yeh ML, Gorski JW, Otten ML, Hwang RY, DeRosa PA, Hickman ZL, Sergot P, Connolly ES Jr (2012) Complement inhibition promotes endogenous neurogenesis and sustained anti-inflammatory neuroprotection following reperfused stroke. PLoS One 7:e38664.

16. Khoyetsyan A, Kacimi R, Tsakanova G, Boyajyan A, Arakelyan A, Yenari MA (2017) Activated complement protein C5a does not affect brain-derived endothelial cell viability and zonula occludens-1 levels following oxygen-glucose deprivation. Brain Circ 3:14-20.

17. Kvietys PR, Granger DN (2012) Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med 52:556-592.

18. Denes A, Thornton P, Rothwell NJ, Allan SM (2010) Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain Behav Immun 24:708-723.

19. Morgan BP, Gasque P (1997) Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 107:1-7.

20. D’Ambrosio AL, Pinsky DJ, Connolly ES (2001) The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol Med 7:367-382.

21. Rynkowski MA, Kim GH, Garrett MC, Zacharia BE, Otten ML, Sosunov SA, Komotar RJ, Hassid BG, Ducruet AF, Lambris JD, Connolly ES (2009) C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. J Cereb Blood Flow Metab 29:98-107.
endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem 293:7195-7208.

32. Zhao XJ, Larkin TM, Lauver MA, Ahmad S, Ducruet AF (2017) Tissue plasminogen activator mediates deleterious complement cascade activation in stroke. PLoS One 12:e0180822.

33. Ahmad S, Elsherbiny NM, Haque R, Khan MB, Ishrat T, Shah ZA, Khan MM, Ali M, Jamal A, Katera DP, Liou GL, Bhatia K (2014) Sesamin attenuates neurotoxicity in mouse model of ischemic brain stroke. Neurotoxicology 45:100-110.

34. Ahmad S, Wang Y, Shaik GM, Burghes AH, Gangwani L (2012) The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy. Hum Mol Genet 21:2745-2758.

35. Clark PR, Manes TD, Pober JS, Kluger MS (2007) Increased ICAM-1 expression causes endothelial cell leakiness, cytoskeletal reorganization and junctional alterations. J Invest Dermatol 127:762-774.

36. Lin CC, Hsieh HL, Shih RH, Chi PL, Cheng SE, Yang CM (2013) Up-regulation of COX-2/PGE2 by endothelin-1 via MAPK-dependent NF-κB pathway in mouse brain microvascular endothelial cells. Cell Commun Signal 11:8.

37. Frey RS, Ushio-Fukai M, Malik AB (2009) NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid Redox Signal 11:791-810.

38. Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, Bagi Z, Ballabh P, Zhang C, Pacher P, Csiszar A (2009) Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 297:H1876-H1881.

39. Strazielle N, Ghersi-Egea JF (2013) Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm 10:1473-1491.

40. Li K, Fazekasova H, Wang N, Peng Q, Sacks SH, Lombardi G, Zhou W (2012) Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology 217:65-73.

41. Ma X, Zhang H, Pan Q, Zhao Y, Chen J, Zhao B, Chen Y (2013) Hypoxia/aglycemia-induced endothelial barrier dysfunction and tight junction protein downregulation can be ameliorated by citicoline. PLoS One 8:e82604.

42. Brown RC, Davis TP (2005) Hypoxia/aglycemia alters expression of occludin and actin in brain endothelial cells. Biochem Biophys Res Commun 327:1114-1123.

43. Song J, Choi SM, Whitcomb DJ, Kim BC (2017) Adiponectin controls the apoptosis and the expression of tight junction proteins in brain endothelial cells through AdipoR1 under beta amyloid toxicity. Cell Death Dis 8:e3102.

44. Cowell RM, Plane JM, Silverstein FS (2003) Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J Neurosci 23:9459-9468.

45. Akaraseenont PC, Tchatriasak K, Thaworn A, Chotewut- takorn S (2002) The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase. Mediators Inflamm 11:17-22.

46. Matsumura K, Cao C, Ozaki M, Morii H, Nakadate K, Watanabe Y (1998) Brain endothelial cells express cyclooxygenase-2 during lipopolysaccharide-induced fever: light and electron microscopic immunocytochemical studies. J Neurosci 18:6279-6289.

47. Cowell RM, Plane JM, Silverstein FS (2003) Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J Neurosci 23:9459-9468.
cellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways. J Immunol 165:4658-4666.

56. Huang F, Cao J, Liu Q, Zou Y, Li H, Yin T (2013) MAPK/ERK signal pathway involved expression of COX-2 and VEGF by IL-1β induced in human endometriosis stromal cells in vitro. Int J Clin Exp Pathol 6:2129-2136.

57. Castellano G, Franzin R, Stasi A, Divella C, Sallustio F, Pontrelli P, Lucarelli G, Battaglia M, Staffieri F, Crovace A, Stallone G, Seelen M, Daha MR, Grandaliano G, Gesualdo I. (2018) Complement activation during ischemia/reperfusion injury induces pericyte-to-myofibroblast transdifferentiation regulating peritubular capillary lumen reduction through pERK signaling. Front Immunol 9:1002.

58. Kraus S, Seger R, Fishelson Z (2001) Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin Exp Immunol 123:366-374.

59. Coulthard LG, Woodruff TM (2015) Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol 194:3542-3548.